Company Overview

Xtant Medical Holdings, Inc. is a U.S.-based medical technology company focused on regenerative medicine products and surgical solutions for the treatment of spinal, orthopedic, and certain neurosurgical conditions. The company operates primarily within the biologics and medical device sectors, developing and distributing implants, allografts, fixation systems, and orthobiologic products used by surgeons in complex musculoskeletal procedures. Its revenue base is largely driven by spinal implant systems, biologic graft products, and related surgical instrumentation sold to hospitals, ambulatory surgery centers, and surgeons.

The company traces its origins to the spinal implant business formerly known as Bacterin International Holdings, Inc., which later rebranded as Xtant Medical Holdings, Inc. as it expanded beyond tissue processing into a broader portfolio of spinal and orthopedic technologies. Xtant has positioned itself as a specialized provider serving spine surgeons seeking biologic and fixation solutions across cervical, thoracolumbar, and sacroiliac procedures. Its strategic positioning has emphasized a combination of biologics expertise, surgeon-focused product development, and a diversified portfolio intended to compete in niche and mid-sized segments of the spinal device market.

Business Operations

Xtant Medical generates revenue through the sale of products across its primary operating categories, including Biologics and Hardware. The biologics portfolio includes demineralized bone matrix products, allografts, synthetic bone graft substitutes, and regenerative tissue products, while the hardware segment includes spinal fixation systems, interbody devices, cervical plating systems, and instrumentation used in spinal surgery. The company maintains relationships with independent distributors and surgeon networks throughout the United States, which represent a major component of its commercial distribution strategy.

Operations are concentrated primarily in the United States, although the company has pursued selective international distribution opportunities through third-party relationships. Xtant controls proprietary product lines and manufacturing capabilities tied to tissue processing, implant design, and surgical instrumentation. The company has also maintained partnerships and licensing arrangements supporting product development and commercialization. Subsidiary and operational activities have historically included tissue processing and biologics manufacturing capabilities associated with the company’s regenerative medicine platform.

Strategic Position & Investments

Xtant Medical’s strategic direction has focused on expanding its spinal hardware portfolio, increasing biologics adoption, and improving operational scale through targeted acquisitions and product launches. The company has invested in next-generation fixation systems, minimally invasive surgical technologies, and regenerative biologic solutions intended to address evolving surgeon demand in spinal fusion and orthopedic reconstruction procedures. Growth initiatives have also included expanding its distributor network and strengthening surgeon education and procedural support capabilities.

A notable strategic transaction was the acquisition of Surgalign Holdings, Inc.’s spinal implant and hardware assets through bankruptcy proceedings, which substantially expanded Xtant’s product offerings and commercial reach in the spine market. The company has also emphasized operational integration and portfolio rationalization following acquisitions. Emerging areas of focus include advanced biologics, synthetic graft materials, and procedural technologies designed to support spinal fusion outcomes and surgical efficiency. Public filings and investor materials consistently identify scale expansion and product portfolio diversification as core strategic priorities.

Geographic Footprint

Xtant Medical is headquartered in Colorado, United States, with primary operational activities centered in the U.S. spine and orthopedic markets. The company maintains domestic manufacturing, tissue processing, distribution, and commercial operations supporting surgeons and healthcare facilities nationwide. Its largest commercial presence remains within the United States, where spinal procedure volumes and biologics utilization represent the company’s principal revenue opportunity.

Outside the United States, Xtant has maintained limited but growing international distribution exposure through commercial partners and regional distributors. Its products have reached select markets in Europe, Asia-Pacific, and Latin America, although international operations remain materially smaller than domestic operations based on publicly available filings and disclosures. The company’s international influence is primarily tied to product distribution rather than large-scale overseas manufacturing or direct operating infrastructure.

Leadership & Governance

Xtant Medical Holdings, Inc. is led by an executive team with experience across medical devices, spinal surgery technologies, biologics, and healthcare operations. The company’s governance structure includes executive leadership, an independent board of directors, and oversight practices aligned with publicly traded company requirements under U.S. securities regulations. Strategic leadership has consistently emphasized operational efficiency, portfolio expansion, surgeon engagement, and long-term growth in the spinal implant and biologics markets.

Key executives identified in recent public filings and company disclosures include:

• Sean E. Browne – President and Chief Executive Officer
• David J. Martin – Chief Financial Officer
• Joshua T. Sutter – Chief Operating Officer
• R. Scott Neagle – General Counsel and Corporate Secretary

The leadership team has communicated a strategic vision centered on expanding market share in spine surgery, integrating acquired assets, and leveraging biologics expertise to strengthen competitive positioning. Governance and operational disclosures referenced in recent SEC filings, including annual reports and investor presentations, support the company’s stated emphasis on disciplined growth and product innovation.